ANGELALIGN

Angelalign (6699.HK) gapped up and surged in the morning session, propelled by an earnings forecast and product upgrade. The stock hit an intraday high of HK$96.1, a new 52-week peak, before settling at HK$93.0, up 16.4% from the previous close of HK$79.9. The company guided 2026 H1 net profit of USD 24-25.4 million, up 69%-78.9% YoY, coupled with the iOrtho 6.2 release that enhanced diagnostic and prescription intelligence. The stock has rallied 70.15% from its 52-week low of HK$54.6 and is up 52.55% YTD, now trading above both the MA20 (HK$77.742) and MA60 (HK$75.156). However, with a trailing PE of 72.07x, the elevated valuation leaves limited room for near-term error.

Angelalign closed up 1.28% at HKD 79.1, staging a bounce-back from the morning low of HKD 77.0 to an intraday high of HKD 80.7 in the afternoon session, eventually settling near the day's average of HKD 79.2. The primary catalyst was the launch of iOrtho 6.2, which enhances diagnostic and prescription capabilities, reinforcing the company's digital orthodontic platform competitiveness. Meanwhile, the company announced an EGM to lift the post-IPO RSU scheme cap to 8% of issued shares and elevated Chairman Feng Dai to an executive role, signaling governance alignment for global expansion. For FY2025, revenue rose 37.8% to USD 370 million, net profit surged 134.7% to USD 28.4 million, and a final and special dividend totaling HKD 5.47 was declared, reflecting improved cash flow and profitability. The stock remains 16.65% below its 52-week high of HKD 94.9 but has gained 29.89% YTD, and has reclaimed both the MA20 (HKD 72.6) and MA60 (HKD 76.3), creating a constructive technical setup alongside strong fundamentals. However, the trailing PE of 61x and the still-significant gap from the peak suggest lingering valuation concerns about sustained high growth.

Angelalign surged 5.84% today to close at HKD 78.80, with an intraday high of HKD 78.95. After opening at HKD 76.00 and briefly dipping to HKD 74.60 in the morning session, the stock staged a single-sided rally and maintained a high-level consolidation in the afternoon. The price has nearly clawed back 60% of its decline from the 52-week high of HKD 94.90. The stock's year-to-date gain stands at 29.39%, and it is now trading above both its 20-day MA (HKD 72.075) and 60-day MA (HKD 76.589), signaling robust momentum. However, the current PE of approximately 60.85x and PB of 3.47x remain elevated, fueling debates over whether current valuations are pricing in sustainable growth, which capped further upside in the afternoon.

Angelalign opened higher and continued to rise, closing the morning session at HKD 77.2, up 5.18%, driven by no specific news but supported by strong earnings. Q4 2025 revenue of HKD 813 million surged 41.89% YoY, net profit of HKD 53.7 million rose 54.43% YoY, EPS of HKD 0.3113 increased 60.45% YoY, and operating profit of HKD 78.3 million skyrocketed 409.46% YoY, with a net margin of 6.60%. The current price of HKD 77.2 remains below the MA60 (HKD 77.86) but has surpassed the MA20 (HKD 70.705), with a YTD gain of 26.77%, a 18.65% retreat from the 52-week high of HKD 94.9, and a 49.61% rebound from the low of HKD 51.6.

Angelalign opened 2.1% higher at HK$73.0 in early morning trading, but quickly retreated to the opening price, with only 6,600 shares traded in the morning session, indicating extremely thin liquidity. The gap-up opening was primarily driven by the company's announcement of the launch of iOrtho Release 6.2, which brings upgraded diagnostic and prescription capabilities, alongside the previously proposed plan to raise the post-IPO RSU scheme cap to 8% of issued shares. On the fundamentals front, Q4 2025 revenue grew 41.89% YoY to HK$813 million, while net profit increased 54.43% YoY, with net profit margin holding steady at 6.6%. However, the stock trades at a steep PE of 56.37x and PB of 3.21x. The stock remains 23.08% below its 52-week high of HK$94.9, though it has gained 19.87% year-to-date. It has fallen below the 60-day moving average of HK$77.99, while the 20-day MA at HK$70.31 provides near-term support. However, recent executive changes, including the COO's reassignment to Chief Strategy Officer, could raise questions about strategic execution continuity.